Levosimendan as treatment option in severe verapamil intoxication: a case report and review of the literature.
Cardiovascular shock due to verapamil intoxication is often refractory to standard resuscitation methods. Recommended therapy includes prevention of further absorption of the drug, inotropic therapy, calcium gluconate, and hyperinsulinemia/euglycemia therapy. Often further measures are needed such as ventricular pacing or mechanical circulatory support. Still, mortality remains high. Levosimendan, an inotropic agent, that enhances myofilament response to calcium, increases myocardial contraction and could therefore be beneficial in verapamil intoxication. Here, we report the case of a 60-year-old patient with clinically severe verapamil poisoning who presented with shock, bradycardia, and sopor. Standard therapy including high-dose inotropes failed to ameliorate the signs of intoxication. But additional therapy with levosimendan led to rapid improvement. Based on this observation, the literature is reviewed focusing on utilization of levosimendan in the treatment of calcium channel blocker overdose. We suggest to consider levosimendan as additional treatment option in patients with cardiovascular shock due to verapamil intoxication that are refractory to standard management.
Osthoff
Mirjam
M
Medical Intensive Care Unit, University Hospital Basel, 4031 Basel, Switzerland.
Bernsmeier
Christine
C
Marsch
Stephan C
SC
Hunziker
Patrick R
PR
Am J Med. 1993 Oct;95(4):431-8
8213877
J Crit Care. 2005 Mar;20(1):114-5
16015526
Anesth Analg. 2009 Mar;108(3):790-2
19224785
Drug Saf. 2003;26(2):65-79
12534324
J Cardiovasc Pharmacol. 1995;26 Suppl 1:S10-9
8907127
N Engl J Med. 2001 May 31;344(22):1721-2
11386285
J Emerg Med. 1991 Sep-Oct;9(5):357-66
1940240
Crit Care Med. 2008 Aug;36(8):2257-66
18664782
J Mol Cell Cardiol. 1995 Sep;27(9):1859-66
8523447
Ann Emerg Med. 1986 Oct;15(10):1221-4
3752656
Acta Anaesthesiol Scand. 2003 Sep;47(8):1038-40
12904199
J Toxicol Clin Toxicol. 1999;37(4):463-74
10465243
Resuscitation. 2003 May;57(2):211-3
12745190
Toxicol Appl Pharmacol. 1997 Aug;145(2):357-62
9266809
J Med Toxicol. 2009 Mar;5(1):3-7
19191208
J Cardiovasc Pharmacol. 2007 Sep;50(3):257-63
17878752
Am J Crit Care. 2007 Sep;16(5):498-503
17724247
Clin Toxicol (Phila). 2008 Jan;46(1):50-6
17926153
J Cardiovasc Pharmacol. 1995 May;25(5):794-801
7630157
Eur Heart J. 2002 Sep;23(18):1422-32
12208222